Sanofi Genzyme and Regeneron present positive dupilumab data in inflammatory conditions

17 June 2016

French pharma major Sanofi’s (Euronext: SAN) USA-based biotech subsidiary Sanofi Genzyme and US firm Regeneron Pharmaceuticals (Nasdaq: REGN) have presented three chunks of new data on dupilumab, the first investigational compound in a new class of immunotherapies.

They have revealed findings for the human monoclonal antibody’s impact in trials of patients with atopic dermatitis, nasal polyposis and uncontrolled persistent asthma at this week’s European Academy of Allergy and Clinical Immunology (EAACI) Congress 2016 in Vienna, Austria.

One of the new data sets presented came in an abstract entitled The effect of dupilumab on vaccine antibody responses in adults with moderate-to-severe atopic dermatitis: a randomized, double-blind, placebo-controlled trial.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK